



Annual Meeting 2016

26 October 2016

9:00 - 12:30

Session room 1A, Upper Level
ACC, Liverpool, United Kingdom

Chairpersons

Catharina Boehme, FIND

Daniela Cirillo, San Raffaele Scientific Institute
NDWG Co-Chairs

About the NDWG

The New Diagnostics Working Group (NDWG) is one of the seven working groups of the Stop TB Partnership. Its mission is to foster development and evaluation of new diagnostics for tuberculosis by serving as a coordination, communication and advocacy platform for all stakeholders in TB diagnostic research and development. The NDWG provides a neutral and overarching platform for coordination at the global level.

Symposium

Overview

At its 2015 Annual Meeting, the New Diagnostics Working Group (NDWG) launched three task forces with the goal of advancing the priorities in TB diagnostics research and development to support the targets of the End TB strategy and the Global Plan to End TB.

This year, we will review progress made since our last annual meeting with a particular focus on the achievements of our Task Force on Tests for progression of latent tuberculosis infection (LTBI) to active disease. The task force coordinator and members will report on the outcomes of an expert workshop convened by the NDWG in July and present newer understanding of the evolving concept of LTBI diagnosis, as well as advanced drafts of the Target product profile (TPP) for a test for incipient TB and the guidelines for evaluation of novel LTBI tests.

Additional presentations will consider the use of existing molecular tests and the perspectives of next generation sequencing for detection of drug resistance in high TB burden countries, and share a recent overview of the biomarker pipeline for TB detection at the point-of-care level, including for paediatric TB.

Agenda overleaf



Agenda

NDWG Annual Meeting 2016

9:00 Introduction

Strategic framework for new diagnostics 2016-2020: Progress towards *Global Plan* goals

Catharina Boehme, FIND, NDWG Co-Chair

9:15-10:45 - Part I

Supporting TB elimination: Advances towards delivering new diagnostics for latent tuberculosis infection (LTBI)

- Setting the scene for LTBI diagnostics
Alberto Matteelli, University of Brescia, Coordinator NDWG Task Force on LTBI and tests of progression
- The evolving concept of LTBI diagnosis: Tests for incipient TB and tests for persistent infection
Frank Cobelens, KNCV and AIGHD
- Target product profile for a test for incipient TB: Making better predictions to improve patient care
Samuel Schumacher, FIND
- Guidance document for the evaluation of TB prediction tests to inform WHO endorsement – An update
Frank Cobelens, KNCV and AIGHD
- Q&A and discussion

Coffee break

11:15-12:00 - Part II

Next Generation Sequencing for improved management of patients with drug resistant TB

- Grading of mutations associated with drug resistance and their use in clinical practice
Daniela Cirillo, San Raffaele Scientific Institute
 - Optimising patient care with existing molecular screening tests in high-burden countries
Camilla Rodrigues, Hinduja Hospital
 - Deeplex-MycTB, an all-in-one test for diagnosis and surveillance of drug-resistant TB
Philip Supply, French National Center for Scientific Research and Genoscreen
-

12:00-12:30 - Part III

Advancing biomarker discovery for TB point-of-care tests

- The biomarker pipeline for active TB detection
Tobias Broger, FIND, Coordinator NDWG Task Force on Biomarkers for TB point-of-care tests
- Biomarkers for paediatric TB and update on standardized SOPs for pediatric sample collection
Rinn Song, Boston Children's Hospital/Harvard Medical School

Wrap-up and close of the meeting

Daniela Cirillo, San Raffaele Scientific Institute, NDWG Co-Chair